Sign in Subscribe
BioMed

🧬 BioMed Pulse · 2026-07-27 02:02 UTC

BIOMED PULSE

Sunday, July 27, 2026 | Your daily briefing on longevity, viruses, and new cures

⚡ TL;DR

The Ebola Bundibugyo virus disease outbreak in DRC and Uganda has now surpassed 2,124 confirmed cases and 828 deaths as of July 15, making it the dominant global health emergency of 2026. Mood: urgent but scientifically active — the PARTNERS treatment trial is enrolling and a first WHO-listed diagnostic test is now deployed. [1] [2] [3]

🦠 OUTBREAKS & VIRUSES

EBOLA BUNDIBUGYO VIRUS DISEASE — DRC AND UGANDA (ACTIVE PHEIC)

  • As of July 15, 2026, cumulative confirmed cases reached 2,124 with 828 confirmed deaths in the DRC, with ongoing cross-border transmission to Uganda. [1]
  • As of July 3, the DRC alone had reported 1,460 confirmed cases and 452 deaths, illustrating the rapid acceleration in case counts over a two-week window. [2]
  • WHO declared the Ebola Bundibugyo virus disease (BVD) outbreak a Public Health Emergency of International Concern (PHEIC) on May 22, 2026, noting it does not yet meet the threshold for pandemic emergency. [4]
  • The outbreak originated in Mongbwalu Health Zone, Ituri Province, DRC; the Institut national de recherche biomedicale (INRB) confirmed Bundibugyo virus on May 14, 2026. [5]
  • Africa CDC and WHO jointly launched a continental preparedness and response plan on June 5, 2026, seeking to raise US $518 million to support African countries in the response. [6]
  • WHO released its first comprehensive clinical management guidelines covering all Ebola and Marburg filovirus types on June 17, 2026, directly in response to the active BVD outbreak. [7]
  • On July 2, 2026, WHO added the first molecular diagnostic test for Bundibugyo virus to its Emergency Use Listing, enabling rapid genetic confirmation from blood samples. [8]
  • Enhanced Ebola airport screening was activated at Washington-Dulles International Airport on May 21 and expanded to Atlanta Hartsfield on May 23, 2026. [9] [10]
  • The PARTNERS clinical trial opened patient enrolment on July 2, 2026 in DRC to evaluate the first potential therapeutic candidates against Bundibugyo virus disease. [3]
  • WHO expert groups assessed candidate vaccines and therapeutics for BVD prevention and treatment as of May 28, 2026; no approved product yet exists for this virus strain.

CYCLOSPORA — UNITED STATES (ACTIVE, EXPANDING)

  • Shredded iceberg lettuce served at Taco Bell locations was identified as the source of Cyclospora cayetanensis infections across five states, with 1,644 people reported sick as of July 17, 2026.
  • The outbreak expanded to four additional states as of July 24, 2026, and CDC is conducting an active cyclosporiasis response with transcripts published July 14 and ongoing.

ANDES HANTAVIRUS — M/V HONDIUS CRUISE SHIP (ACTIVE, MULTI-COUNTRY)

  • A fifth WHO Disease Outbreak News report published July 2, 2026 confirmed the Andes hantavirus (ANDV) outbreak linked to cruise ship M/V Hondius remains under active multi-country investigation.
  • The outbreak was first notified to WHO on May 2, 2026; early reports identified seven cases including two laboratory-confirmed Andes hantavirus infections aboard a vessel carrying 147 passengers and crew.
  • CDC provided hantavirus response transcript updates through June 24, 2026, with the risk to the general American public described as extremely low.

WEST NILE VIRUS — UNITED STATES

  • CDC reported an early and record-setting West Nile virus season ahead of the July 4 holiday weekend, urging mosquito bite prevention nationwide.

NIPAH VIRUS — INDIA AND BANGLADESH

  • Kerala State, India confirmed one laboratory-confirmed Nipah virus (NiV) case in Kozhikode district on June 11, 2026; the adult male patient developed neurological symptoms and was hospitalized June 10.
  • Bangladesh notified WHO on February 3, 2026 of a confirmed NiV case in Rajshahi Division; the patient developed fever and neurological symptoms on January 21.

MPOX — RECOMBINANT STRAIN (GLOBAL SIGNAL)

  • WHO reported in February 2026 two cases of a recombinant monkeypox virus (MPXV) strain combining genomic elements of both clade Ib and clade IIb, a known but newly documented natural process when two strains co-infect one individual.

AVIAN INFLUENZA A(H9N2) — ITALY

  • Italy notified WHO on March 21, 2026 of a human case of avian influenza A(H9N2) in an adult male who had returned from Senegal; next-generation sequencing confirmed the subtype.

MEASLES — BANGLADESH AND GLOBAL

  • Bangladesh reported 19,161 suspected measles cases and 2,897 laboratory-confirmed cases across 58 of 64 districts as of April 4, 2026, reflecting a nationwide surge.
  • Globally, measles infected 10.3 million people in 2023 according to CDC-WHO data, underscoring the ongoing rollback of vaccination gains.

YELLOW FEVER — GLOBAL

  • From January 1 to May 26, 2026, six countries reported 79 human yellow fever infections; transmission that began surging in the Americas in 2025 carried into 2026.

E. COLI — FROZEN BLUEBERRIES, UNITED STATES

  • CDC issued a food safety alert on July 7, 2026 warning consumers not to eat recalled frozen blueberries linked to an E. coli outbreak.

SALMONELLA — BACKYARD POULTRY, UNITED STATES

  • A Salmonella outbreak linked to backyard poultry reported 34 people sick across 13 states as of April 23, 2026, with over a quarter of cases in children under 5 years old in an updated notice from May 14, 2026.

MARBURG VIRUS — ETHIOPIA 2025 (RETROSPECTIVE)

  • A Europe PMC retrospective descriptive study published July 1, 2026 documented the epidemiology and containment of the first Marburg virus disease outbreak in Ethiopia in 2025.

🧬 LONGEVITY & AGING

DEMENTIA PREVENTION — WHO GUIDELINES UPDATE

  • WHO released updated guidelines on July 15, 2026 stating that up to 45% of dementia risk could be prevented or delayed through evidence-based interventions across the life course, with country-level recommendations included.
  • The guidelines identify modifiable risk factors for cognitive decline and are intended to give governments actionable prevention targets for the first time in this comprehensive form.

NAD+ AND BONE REPAIR IN AGING

  • A study published in Bioactive Materials (June 27, 2026) describes a senescent metabolism-modulating hierarchical scaffold that restores NAD+ homeostasis and redox balance to promote bone repair in aged tissue.
  • NAD+ depletion is a hallmark of cellular senescence; the scaffold approach targets metabolic dysfunction in aged bone cells rather than only structural replacement.

KAEMPFEROL FROM MORINGA AND LONGEVITY IN DROSOPHILA

  • Research published in Toxicology Reports (June 25, 2026) found that kaempferol derived from Moringa oleifera increases lifespan and reduces efavirenz-induced functional senescence in Drosophila melanogaster.
  • The finding is notable for its senescence angle: kaempferol appeared to counter drug-induced accelerated aging at the cellular-functional level in the fly model.

COLLAGEN XVII AND EPIDERMAL STEM CELL PHOTOAGING

  • A study published in Annals of Medicine (July 16, 2026) showed recombinant human collagen XVII protects epidermal stem cells from blue-light-induced photoaging by downregulating the Notch signaling pathway.
  • Epidermal stem cell preservation is a key mechanism in skin longevity; Notch pathway suppression by collagen XVII offers a potential topical or therapeutic target.

TELOMERE REPAIR IN CANCER CELLS

  • Research published in Nucleus (July 23, 2026) examined repair and misrepair of telomeric DNA in cancer cells treated with doxorubicin, tracking dynamic interactions with PML nuclear bodies and lamin B1.
  • Telomere misrepair is a double-edged mechanism relevant to both cancer survival and normal cellular aging, as unstable telomeres drive senescence or genomic chaos.

TAU AND NUCLEAR MECHANOTRANSDUCTION IN NEURONS

  • A study in Nucleus (July 7, 2026) found that the mechanically sensitive nuclear envelope protein emerin links nuclear mechanotransduction to tau-induced cytoskeletal remodeling in neurons, a pathway implicated in tauopathies including Alzheimer's disease.
  • The emerin-tau connection suggests nuclear structural integrity may be an upstream target in neurodegeneration research.

HYPERTENSION AND FRAILTY IN OLDER ADULTS — INDIA

  • A letter published in Blood Pressure (July 7, 2026) discussed associations between hypertension and frailty among middle-aged and older adults based on data from the Longitudinal Ageing Study in India, highlighting a clinically underappreciated bidirectional relationship.

CANCER BURDEN PROJECTION — WHO

  • WHO reported on July 8, 2026 that new cancer cases are projected to nearly double by 2050 from the current 20.6 million new cases annually, with approximately 10 million cancer deaths per year today.
  • WHO framed cancer as an aging-linked disease emergency requiring urgent scale-up of screening, prevention, and treatment infrastructure globally.

P16-INK4A SENESCENCE MARKER — VALIDATION ISSUE

  • A methods paper in Islets (July 21, 2026) highlighted the critical importance of antibody validation when detecting the senescence marker p16-INK4A by immunohistochemistry in pancreas tissue, signaling a reproducibility concern in aging-biology research.
  • Accurate p16-INK4A quantification underpins senescent cell burden studies and senolytics clinical trial endpoints.

TOBACCO AND LIVER DISEASE BURDEN

  • A study in Journal of Diabetes & Metabolic Disorders (July 3, 2026) analyzed the global burden of metabolic dysfunction-associated steatotic liver disease (MASLD) attributable to tobacco from 1990 to 2023 with projections to 2038, finding tobacco a significant and underappreciated MASLD driver.

💊 NEW CURES & APPROVALS

MOMELOTINIB DIHYDROCHLORIDE — GLAXOSMITHKLINE (OJJAARA)

  • GlaxoSmithKline received an FDA supplemental approval (SUPPL AP) for OJJAARA (momelotinib dihydrochloride), a JAK1/JAK2/ACVR1 inhibitor used for myelofibrosis, under NDA216873.
  • Momelotinib's ACVR1 inhibition also addresses anemia in myelofibrosis patients, differentiating it from earlier JAK inhibitors used for this aging-associated blood cancer.

RUXOLITINIB PHOSPHATE — INCYTE CORP (JAKAFI)

  • Incyte Corporation received a supplemental FDA approval for JAKAFI (ruxolitinib phosphate), a JAK1/JAK2 inhibitor used in myelofibrosis and polycythemia vera, under NDA202192.
  • Ruxolitinib was the first JAK inhibitor approved for myelofibrosis and remains a standard of care in the management of this disease.

PITOLISANT HYDROCHLORIDE — NOVITIUM PHARMA

  • Novitium Pharma received an original FDA approval (ORIG AP) for pitolisant hydrochloride under ANDA218495; pitolisant is a histamine H3 receptor antagonist/inverse agonist indicated for narcolepsy and associated excessive daytime sleepiness.

CANAGLIFLOZIN — TEVA PHARMACEUTICALS USA

  • Teva Pharmaceuticals USA received an original tentative FDA approval (ORIG TA) for canagliflozin under ANDA210451; canagliflozin is an SGLT2 inhibitor used in type 2 diabetes with established cardiovascular and renal protective benefits.

TOLVAPTAN — TEVA PHARMACEUTICALS INC

  • Teva Pharmaceuticals Inc received an original FDA approval for tolvaptan under ANDA216933; tolvaptan is a vasopressin V2 receptor antagonist used in autosomal dominant polycystic kidney disease and hyponatremia.

FLUVOXAMINE MALEATE — ZYDUS PHARMACEUTICALS

  • Zydus Pharmaceuticals received an original FDA approval for fluvoxamine maleate under ANDA220447; fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) used in obsessive-compulsive disorder and social anxiety disorder.

LEUPROLIDE MESYLATE — ACCORD (CAMCEVI ETM)

  • Accord received a supplemental FDA approval for CAMCEVI ETM (leuprolide mesylate), a GnRH agonist used in advanced prostate cancer, under NDA219745.

LENALIDOMIDE — BRISTOL MYERS SQUIBB (REVLIMID)

  • Bristol Myers Squibb received a supplemental FDA approval for REVLIMID (lenalidomide), an immunomodulatory agent used in multiple myeloma and myelodysplastic syndromes, under NDA021880.

🧪 CLINICAL TRIALS

ADENOSINE A2A RECEPTOR ANTAGONIST VG081821AC — PARKINSON'S DISEASE

  • A Phase IIb trial registered July 24, 2026 (NCT07725562) is evaluating the oral drug VG081821AC in patients with early to mid-stage Parkinson's disease; the mechanism is adenosine A2A receptor blockade aimed at improving motor function without the dyskinesia associated with levodopa.
  • The trial targets an aging-predominant neurodegenerative disease and represents a non-dopaminergic approach to motor symptom control at early disease stages.

DOUBLE-FILTRATION PLASMAPHERESIS FOR MICROPLASTICS AND PFAS REDUCTION

  • A prospective within-subject biomarker study (NCT07658443, registered July 24, 2026) is evaluating whether clinically prescribed double-filtration plasmapheresis (DFPP) reduces circulating microplastic, nanoplastic-associated particle, and PFAS concentrations in peripheral blood in 20 participants.
  • Environmental toxin accumulation including PFAS and microplastics is an emerging proposed contributor to accelerated biological aging and metabolic disease.

PRECISION EHR LAB COMMUNICATION FOR OLDER ADULTS (65+)

  • A trial (NCT07391904, registered July 24, 2026) is testing a personalized electronic health record lab result communication tool for adults aged 65 and older and their providers, replacing uniform lab reports with individualized, patient-context-aware communications.
  • Improving health literacy and actionability of lab data in older adults is a care-quality and self-management longevity strategy.

BUNDIBUGYO VIRUS TREATMENT — PARTNERS TRIAL (DRC, ACTIVE)

  • The PARTNERS clinical trial opened patient enrolment on July 2, 2026 in the DRC for the first ever therapeutic evaluation in Bundibugyo virus disease, a major milestone in responding to the active PHEIC. [3]
  • WHO convened expert groups in May 2026 to assess candidate vaccines and therapeutics for BVD; the PARTNERS trial is the direct result of that international scientific mobilization. [3]

ANTIRETROVIRAL METABOLIC EFFECTS — INSTI WEIGHT GAIN STUDY

  • Trial NCT05652478 (registered July 24, 2026 update) is a Phase 2 randomized study examining early metabolic effects of integrase strand transfer inhibitors (INSTIs) in healthy volunteers, addressing the mechanism behind HIV drug-induced weight gain linked to diabetes and cardiovascular disease risk.

NEOADJUVANT CHEMOIMMUNOTHERAPY IN RECTAL CANCER

  • Trial NCT07104604 (registered July 24, 2026) is evaluating radiotherapy combined with tislelizumab (anti-PD-1), liposomal irinotecan, and capecitabine in patients aged 18-75 with pMMR locally advanced mid-lower rectal adenocarcinoma.

PLX038 IN MYC/MYCN-AMPLIFIED BRAIN TUMORS

  • Trial NCT06161519 (active, updated July 24, 2026) is investigating PLX038 in primary CNS tumors containing MYC or MYCN amplifications; approximately 30% of brain tumors are malignant and 35% of those patients die within 5 years, defining the urgent need.

📢 PUBLIC HEALTH

CHILDHOOD IMMUNIZATION — GLOBAL COVERAGE UPDATE

  • In 2025, 90% of infants globally (approximately 116 million) received at least one DTP vaccine dose, and 85% (approximately 110 million) completed the full three-dose series, per the WHO-UNICEF 2026 WUENIC release.
  • Coverage gains persist despite conflict and vaccine hesitancy, though gaps remain in fragile states.

U.S. WITHDRAWAL FROM WHO — COMPLETED

  • The United States formally completed its withdrawal from the World Health Organization on January 22, 2026, citing COVID-19 response failures and politicization, pivoting to bilateral health partnerships.
  • The withdrawal has direct implications for U.S. participation in PHEIC coordination, including the active Ebola Bundibugyo PHEIC response.

CYCLOSPORA AT TACO BELL — CONSUMER ALERT

  • CDC confirmed shredded iceberg lettuce at Taco Bell in five states, now expanded to nine states, is the source of 1,644+ Cyclospora infections; consumers should avoid the product and seek care if experiencing prolonged diarrhea.

E. COLI — FROZEN BLUEBERRIES RECALL

  • CDC warns consumers not to eat recalled frozen blueberries linked to an active E. coli outbreak as of July 7, 2026; full recall details posted at CDC food safety alert page.

DRUG-RESISTANT BACTERIA — SHARP RISE REPORTED

  • A CDC report released September 23, 2025 documented a dramatic increase in dangerous drug-resistant bacteria in the United States, reinforcing antimicrobial resistance as a chronic public health threat.

NEW WORLD SCREWWORM — CDC EMERGENCY OPERATIONS CENTER ACTIVATED

  • CDC activated its Emergency Operations Center on June 12, 2026 to respond to a New World Screwworm (Cochliomyia hominivorax) threat; this parasitic fly can cause myiasis in humans and animals and had not previously required CDC EOC activation.

UNSAFE FOOD — WHO GLOBAL BURDEN ESTIMATE

  • WHO published new estimates on June 4, 2026 showing unsafe food causes 866 million illnesses and 1.5 million deaths annually worldwide; children under 5 face nearly three times the illness risk of older individuals.

WEST NILE SEASON — EARLY AND RECORD

  • CDC flagged on July 1, 2026 that the 2026 West Nile virus season is running earlier than historical norms with record case counts; repellent use and eliminating standing water near homes remain the key preventive actions.

INFANT BOTULISM — NARA ORGANICS FORMULA RECALLED

  • CDC on June 13, 2026 urged parents to immediately stop using Nara Organics Whole Milk Organic Infant Formula following confirmed links to an infant botulism outbreak; this is the first infant botulism cluster linked to powdered formula in U.S. history.

This briefing is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider for personal health decisions.

📎 Sources

  1. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  2. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  3. Patient enrolment begins in a scientific trial to identify the… — WHO News
  4. First meeting of the IHR Emergency Committee regarding the epi… — WHO News
  5. Ebola disease caused by Bundibugyo virus, Democratic Republic … — WHO Disease Outbreak News
  6. Africa CDC and WHO launch joint continental Ebola response plan — WHO News
  7. WHO issues comprehensive guidelines on filovirus disease, incl… — WHO News
  8. WHO adds first diagnostic test for Ebola Bundibugyo virus to i… — WHO News
  9. Enhanced Ebola Airport Screening Begins at Washington-Dulles I… — CDC Newsroom
  10. Enhanced Ebola Airport Screening Expands to Atlanta — CDC Newsroom

Curated from official sources — WHO/CDC/ECDC/openFDA/ClinicalTrials.gov/Europe PMC. Informational only — not medical advice.
Serial 20260727-02-v40 · 2026-07-27 02:02 UTC · pulse.uzylab.com

Read next